Mustang Bio reports initial data on MB-105 in prostate cancer

• Mustang Bio (NASDAQ:MBIO) presents one patient‘s experience on the Phase 1 trial of MB-105, a prostate stem cell antigen (PSCA) chimeric antigen receptor (CAR) T administered to patients with PSCA-positive metastatic castration-resistant prostate cancer (mCRPC) at the virtual 27^th Annual Prostate Cancer Foundation Scientific Retreat.
• In a 73-year-old male patient, treated with MB-105 and lymphodepletion (a standard CAR T pre-conditioning regimen) after failing eight prior therapies, MB-105 demonstrated a 94% reduction in prostate-specific antigen (PSA), near complete reduction of measurable soft tissue metastasis, and improvement in bone metastases on day 28.
• The therapy was associated with cytokine release syndrome, which was clinically managed with tocilizumab (anti-IL-6 receptor antibody), and hemorrhagic cystitis requiring transfusion which clinically resolved in 30 days.
• The Phase 1 trial will continue to enroll up to 33 patients. Its primary endpoints are to define safety and optimal dosing of PSCA CAR T cells in treating patients with PSCA-positive mCRPC.
• Secondary endpoints include assessing the expansion and persistence of PSCA CAR T cells, the clinical response based on Prostate Cancer Working Group 3 criteria, survival outcomes and serum cytokine profiles.
• https://seekingalpha.com/news/3625675-mustang-bio-reports-initial-data-on-mbminus-105-in-prostate-cancer